Its a major driver for weight loss, as research shows that it is an effective tool to lose weight, especially if someone suffers from obesity
Essentially, GLP-1 and GIP communicate with each other
For a full overview of what retatrutide's cardiovascular data shows, see our cardiovascular outcomes guide
GLP1 medications have other benefits, as well
The major cardiovascular safety trials The SUSTAIN-6 trial enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk, following them for two years on semaglutide 0.5 mg or 1.0 mg weekly versus placebo
Since every metabolism is different, our providers will help you select the option that best matches your health needs